This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2008 May 1;26(13):2228-30; author reply 2230-1.

doi: 10.1200/JCO.2007.15.9186.

KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature

Aurélien de Reyniès, Valérie Boige, Gérard Milano, Jean Faivre, Pierre Laurent-Puig

PMID: 18445856
DOI: 10.1200/JCO.2007.15.9186

Comment

KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature

Aurélien de Reyniès et al. J Clin Oncol. 2008.

. 2008 May 1;26(13):2228-30; author reply 2230-1.

doi: 10.1200/JCO.2007.15.9186.

Authors

Aurélien de Reyniès, Valérie Boige, Gérard Milano, Jean Faivre, Pierre Laurent-Puig

PMID: 18445856
DOI: 10.1200/JCO.2007.15.9186

No abstract available

PubMed Disclaimer

Comment on

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA 3rd, Poplin EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ. Khambata-Ford S, et al. J Clin Oncol. 2007 Aug 1;25(22):3230-7. doi: 10.1200/JCO.2006.10.5437. J Clin Oncol. 2007. PMID: 17664471 Clinical Trial.

Similar articles

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. Di Nicolantonio F, et al. J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10. J Clin Oncol. 2008. PMID: 19001320
[Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].
Nozawa K, Watanabe T. Nozawa K, et al. Gan To Kagaku Ryoho. 2010 May;37(5):791-4. Gan To Kagaku Ryoho. 2010. PMID: 20495308 Japanese.
Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?
Cremolini C, Loupakis F, Ruzzo A, Perrone G, Rulli E, Vincenzi B, Tonini G, Graziano F, Muda AO, Falcone A. Cremolini C, et al. J Clin Oncol. 2010 Apr 10;28(11):e173-4; author reply e175-6. doi: 10.1200/JCO.2009.26.6148. Epub 2010 Feb 22. J Clin Oncol. 2010. PMID: 20177018 No abstract available.
To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer.
Kim R, Kubal T. Kim R, et al. Clin Colorectal Cancer. 2012 Jun;11(2):85-7. doi: 10.1016/j.clcc.2011.10.005. Epub 2011 Dec 9. Clin Colorectal Cancer. 2012. PMID: 22169039 Review. No abstract available.
Cetuximab in metastatic colorectal cancer.
Broadbridge VT, Karapetis CS, Price TJ. Broadbridge VT, et al. Expert Rev Anticancer Ther. 2012 May;12(5):555-65. doi: 10.1586/era.12.25. Expert Rev Anticancer Ther. 2012. PMID: 22594891 Review.

See all similar articles

Cited by

Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients.
Guinney J, Ferté C, Dry J, McEwen R, Manceau G, Kao KJ, Chang KM, Bendtsen C, Hudson K, Huang E, Dougherty B, Ducreux M, Soria JC, Friend S, Derry J, Laurent-Puig P. Guinney J, et al. Clin Cancer Res. 2014 Jan 1;20(1):265-272. doi: 10.1158/1078-0432.CCR-13-1943. Epub 2013 Oct 29. Clin Cancer Res. 2014. PMID: 24170544 Free PMC article.
Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.
McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Thibodeau SN, Grothey A, Morton RF, Goldberg RM. McLeod HL, et al. J Clin Oncol. 2010 Jul 10;28(20):3227-33. doi: 10.1200/JCO.2009.21.7943. Epub 2010 Jun 7. J Clin Oncol. 2010. PMID: 20530282 Free PMC article. Clinical Trial.
Toward Targeted Therapies in Oesophageal Cancers: An Overview.
Bregni G, Beck B. Bregni G, et al. Cancers (Basel). 2022 Mar 16;14(6):1522. doi: 10.3390/cancers14061522. Cancers (Basel). 2022. PMID: 35326673 Free PMC article. Review.
[Molecular targets for colon cancer. VEGF, EGFR - and what else?].
Röcken C. Röcken C. Pathologe. 2008 Nov;29 Suppl 2:200-3. doi: 10.1007/s00292-008-1041-z. Pathologe. 2008. PMID: 18810446 Review. German.
A Gene Expression Signature Predicts Bladder Cancer Cell Line Sensitivity to EGFR Inhibition.
Goodspeed A, Jean A, Theodorescu D, Costello JC. Goodspeed A, et al. Bladder Cancer. 2018 Jul 30;4(3):269-282. doi: 10.3233/BLC-170161. Bladder Cancer. 2018. PMID: 30112438 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal